Boehringer Ingelheim

News

NICE blocks wider use of Jardiance, Forxiga in heart failure

Eli Lilly and Boehringer Ingelheim's Jardiance and AstraZeneca's Forxiga have not been recommended for NHS use as a treatment for symptomatic chronic heart failure (CHF) w

News

How effective data management can support NHS Trusts to hit their targets

Roche, Boehringer tap biosensor firms for patient studies

Roche and Boehringer Ingelheim have both formed partnerships with tech companies this week to develop and deploy wearable biosensor te

News

Boehringer, Takeda make it into global top 15 employer list

Boehringer Ingelheim and Takeda are the only two pharmaceutical groups to be named among the 15 Global Top Employers for 2023, an award dedicated to companies that enrich the workplace envi

News

BI, Click Therapeutics expand collaboration to PDT for schiz...

Boehringer Ingelheim (BI) and Click Therapeutics have announced they are expanding their

News

NICE backs use of Boehringer's Ofev in IPF from diagnosis

Thousands more UK patients with idiopathic pulmonary fibrosis (IPF) will now be eligible for treatment with Boehringer Ingelheim's Ofev, following new guidance from health technology assess

News